The published research on epitalon consists mainly of cell-culture studies reporting telomerase activation and telomere lengthening, rodent and fruit-fly lifespan studies, and a small human literature, nearly all of it from one research group in St. Petersburg, Russia. We found no large randomized human trial of epitalon, and much of the human work often cited for it actually studied epithalamin, a pineal gland extract the FDA treats as a different substance.
That does not make the work worthless. It makes it narrow, concentrated in one institution, and in places hard to check, which is the frame for everything below.
What it is
Epitalon (also spelled epithalon, and sometimes written AEDG) is a synthetic tetrapeptide: alanine, glutamic acid, aspartic acid and glycine. It was developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology as a synthetic analog of epithalamin, a polypeptide extract of bovine pineal gland that the same program had studied earlier.
The distinction matters more than it seems. The FDA's July 2026 briefing document states that the agency considers epitalon and epithalamin different substances: one is a defined four-residue molecule, the other a mixture extracted from animal tissue. Several of the most-cited animal and human studies in this literature used the extract.
The telomerase claims and the cell studies behind them
The claim most often attached to epitalon is that it activates telomerase, the enzyme that rebuilds telomeres, the protective caps on chromosome ends that shorten as cells divide.
Two short papers by Khavinson and colleagues in the Bulletin of Experimental Biology and Medicine are the foundation:
- 2003. Adding epitalon to cultures of telomerase-negative human fetal fibroblasts induced expression of telomerase's catalytic subunit, telomerase activity and telomere elongation.
- 2004. In human fetal lung fibroblasts that had stopped dividing at the 34th passage, epitalon was reported to lengthen telomeres to early-passage levels, and the treated cells made 10 extra divisions beyond the control.
Both are cell-culture studies in a single fibroblast type, from the group that developed the peptide.
The first independent replication we found is recent. Al-Dulaimi and colleagues at Brunel University London (Biogerontology, 2025) treated breast cancer cell lines and normal epithelial and fibroblast cells with epitalon and reported telomere lengthening in both. In normal cells they attributed it to increased hTERT expression and telomerase activity. In the cancer cell lines, they attributed it to a different mechanism, alternative lengthening of telomeres. The paper was later corrected.
Telomerase activation in a culture dish is a result about cells. We found no study showing that longer telomeres in cultured fibroblasts translate into longer lives in people. The 2025 finding that epitalon also lengthened telomeres in cancer cell lines is one that needs follow-up rather than dismissal.
The animal lifespan studies
Epithalamin, the extract. Anisimov, Mylnikov and Khavinson (Mechanisms of Ageing and Development, 1998) reported that the pineal extract increased mean lifespan by 11 to 31 percent in female fruit flies, two strains of mice and a strain of rats. In one mouse strain, SHR, the mortality rate did not change.
Epitalon, the synthetic peptide. Anisimov and colleagues (Biogerontology, 2003) treated female SHR mice, 54 per group, from three months of age until natural death. Epitalon did not change mean lifespan, food intake or body weight. The authors reported a 13.3 percent longer lifespan among the last 10 percent of survivors, a 12.3 percent longer maximum lifespan, fewer chromosome aberrations in bone marrow cells, and less leukemia, with no change in total tumor incidence.
The more defensible summary is the plain one: in the synthetic-peptide study, average lifespan did not move, and the positive findings were in the tail of the survival curve and in secondary measures. These studies also come from the St. Petersburg group and its collaborators.
The human literature, and its limits
Mostly the extract, mostly one group. The best-known human paper, Khavinson and Morozov (Neuro Endocrinology Letters, 2003), described older adults followed for six to eight years at the St. Petersburg institute and the Institute of Gerontology in Kiev and reported lower mortality in groups given thymalin (a thymus extract), epithalamin, or both. Those are extracts, not epitalon, and the design reported in the abstract is not a modern randomized controlled trial.
Melatonin studies. Korkushko and colleagues published several papers in the 2000s on pineal preparations and melatonin rhythms in elderly people. The FDA's briefing quotes a Khavinson review stating that epithalamin and epitalon roughly doubled melatonin levels in elderly subjects with reduced pineal function, with no significant effect in those with preserved function or in young people.
The most recent trial. The FDA briefing describes Ivko and colleagues (2021), a randomized, placebo-controlled study of the AEDG peptide in 75 healthy women aged 40 to 50, mostly night-shift workers, measuring a urinary melatonin metabolite and clock-gene expression in blood cells. The FDA noted that the study did not report safety data. A related Russian-language paper by the same authors appears in Advances in Gerontology (2020).
What the FDA found. For the July 2026 meeting, epitalon was nominated for insomnia. FDA staff concluded there was a lack of evidence for that use, that they found no studies of epitalon in patients with insomnia, and that neither the nominations nor their search identified clinical studies assessing epitalon's safety in humans. Two of the 26 articles submitted with the nomination were in Russian, and the agency said it could not locate one cited reference in English.
The structural problem is the same throughout. The human work is small, largely from the developers' own network, often published in Russian or in short-format journals, and frequently about the extract rather than the synthetic peptide. That limits how far anyone outside the group can check it.
Regulatory status
Epitalon is not FDA-approved for any use. It was among the peptides the FDA had placed in Category 2 of its compounding policy and was removed from it in April 2026 after its nominator withdrew. At the July 24, 2026 session of the Pharmacy Compounding Advisory Committee, FDA staff proposed against adding it to the 503A bulks list, and the committee voted to recommend it. We could not find the vote tally in a published source. The recommendation is not binding and is not an approval, and we found no proposed rule as of this writing. Our coverage of the interim access policy now under White House review explains what is and is not known about which peptides it would cover.
For the rest of this class, see our review of the longevity peptides and our comparison of MOTS-c and NAD+.
Frequently asked questions
Does epitalon lengthen telomeres?
In cell culture, two studies from the developing group (2003 and 2004) and one independent study (Brunel University London, 2025) reported telomere lengthening in human cells. We found no human study showing that epitalon lengthens telomeres in people.
Is epitalon the same as epithalamin?
No. Epithalamin is a polypeptide extract of bovine pineal gland. Epitalon is a synthetic four-amino-acid peptide developed as its analog. The FDA treats them as different substances, and several frequently cited studies used the extract.
Did epitalon extend lifespan in animals?
In a 2003 study of female mice, it did not change average lifespan, though the authors reported longer survival among the longest-lived animals. The larger lifespan increases reported in 1998 were for epithalamin, the extract.
Is epitalon legal?
It is not an approved drug in the United States. Its compounding status is under review after the July 2026 advisory vote.
Sources:
- Khavinson et al., Bull Exp Biol Med, 2003 (telomerase in human fetal fibroblasts)
- Khavinson et al., Bull Exp Biol Med, 2004 (fibroblast division limit)
- Al-Dulaimi et al., Biogerontology, 2025 (normal and cancer human cell lines)
- Al-Dulaimi et al., correction, Biogerontology, 2025
- Anisimov, Mylnikov and Khavinson, Mech Ageing Dev, 1998 (epithalamin; flies, mice, rats)
- Anisimov et al., Biogerontology, 2003 (epitalon in female SHR mice)
- Khavinson and Morozov, Neuro Endocrinol Lett, 2003 (thymalin and epithalamin in older adults)
- Korkushko et al., Bull Exp Biol Med, 2006 (epithalamin in elderly subjects)
- Ivko et al., Adv Gerontol, 2020 (AEDG peptide and circadian genes; in Russian)
- FDA briefing document, Epitalon-related bulk drug substances, PCAC, July 2026
- FDA, Certain bulk drug substances for use in compounding that may present significant safety risks
- FDA, July 23 to 24, 2026 meeting of the Pharmacy Compounding Advisory Committee
- Holland & Knight, Peptides at a crossroads, October 2026
No compound discussed in this review is FDA-approved. Nothing above is dosing guidance or a treatment claim. Research use only.
For research use only · Not for human or veterinary use · No research compound discussed here is FDA-approved for any indication